Phase II failures: 2008–2010
The DOI matches its Crossref record.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, the decreasing success rate of drugs entering clinical trials (29) suggests that the pharmacology of target-based drug candidates predicts their therapeutic efficacy and toxicity poorly.”
From Cytokine Response Is Determined by Duration of Receptor and Signal Transducers and Activators of Transcription 3 (STAT3) Activation (2013) · cites this paper as [29]
In the citing paper
“In the development of pharmaceutical drugs over 80% fail to reach ‘Phase III’ effectiveness trials, even after considerable investment [4].”
From Exploratory studies to decide whether and how to proceed with full-scale evaluations of public health interventions: a systematic review of guidance (2018) · cites this paper as [4]
Citations
Cites
Still being checked.
Cited by
Items 201–300 of 624
Prina‐Mello, A., Jain, N., Liu, B., Kilpatrick, J. I., Tutty, M. A., Bell, A. P., Jarvis, S., Volkov, Y., & Movia, D. (2017) · Tissue and Cell · doi:10.1016/j.tice.2017.11.003 · Cited by 34
Gilbert, I. H. (2013) · Parasitology · doi:10.1017/s0031182013001017 · Cited by 32
Microphysiological systems: What it takes for community adoption
Hargrove-Grimes, P., Low, L. A., & Tagle, D. A. (2021) · Experimental Biology and Medicine · doi:10.1177/15353702211008872 · Cited by 35
Mignani, S. M., Tripathi, V. D., Soam, D., Tripathi, R. P., Das, S., Singh, S., Gandikota, R., Laurent, R., Karpus, A. O., Caminade, A., et al. (2021) · Biomacromolecules · doi:10.1021/acs.biomac.1c00355 · Cited by 36
Physiology restores purpose to evolutionary biology
Noble, R., & Noble, D. (2022) · Biological Journal of the Linnean Society · doi:10.1093/biolinnean/blac049 · Cited by 36
Tilp, C., Kapur, V., Loging, W., & Erb, K. J. (2013) · International Journal for Parasitology · doi:10.1016/j.ijpara.2012.12.003 · Cited by 32
Decision Making from Phase II to Phase III and the Probability of Success: Reassured by “Assurance”?
Carroll, K. J. (2013) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2013.813527 · Cited by 35
LiCABEDS II. Modeling of Ligand Selectivity for G-Protein-Coupled Cannabinoid Receptors
Ma, C., Wang, L., Yang, P., Myint, K. Z., & Xie, X. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci3003914 · Cited by 31
Bradley, S. J., & Tobin, A. B. (2016) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-140012 · Cited by 32
Lane, A. N., Higashi, R. M., & Fan, T. W. ‐. (2016) · Metabolomics · doi:10.1007/s11306-016-1065-y · Cited by 34
Improving Cancer Drug Discovery by Studying Cancer across the Tree of Life
Somarelli, J. A., Boddy, A. M., Gardner, H. L., DeWitt, S. B., Tuohy, J. L., Megquier, K., Sheth, M. U., Hsu, S. D., Thorne, J. L., London, C. A., et al. (2019) · Molecular Biology and Evolution · doi:10.1093/molbev/msz254 · Cited by 34
van de Steeg, E., Kleemann, R., Jansen, H. T., van Duyvenvoorde, W., Offerman, E. H., Wortelboer, H. M., & DeGroot, J. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.208595 · Cited by 28
Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody–drug conjugates
Sapra, P., Betts, A. M., & Boni, J. P. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2013.827405 · Cited by 30
Kenakin, T. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00958-9 · Cited by 35
Göttlich, C., Müller, L. C., Kunz, M., Schmitt, F., Walles, H., Walles, T., Dandekar, T., Dandekar, G., & Nietzer, S. (2016) · Journal of Visualized Experiments · doi:10.3791/53885 · Cited by 29
Kleikers, P. W. M., Hooijmans, C. R., Göb, E., Langhauser, F., Rewell, S. S. J., Radermacher, K. A., Ritskes-Hoitinga, M. J., Howells, D. W., Kleinschnitz, C., & Schmidt, H. H. H. W. (2015) · Scientific Reports · doi:10.1038/srep13428 · Cited by 33
Vibration in mice: A review of comparative effects and use in translational research
Reynolds, R. P., Li, Y., Garner, A., & Norton, J. N. (2018) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12024 · Cited by 37
Clinical Implementation of Precision Medicine in Gastric Cancer
Jeon, J., & Cheong, J. (2019) · Journal of the Korean Gastric Cancer Association · doi:10.5230/jgc.2019.19.e25 · Cited by 31
Redefining Approaches to Asthma
Arron, J. R., Scheerens, H., & Matthews, J. G. (2013) · Advances in pharmacology · doi:10.1016/b978-0-12-404717-4.00001-9 · Cited by 30
Translational semantics and infrastructure: another search for the emperor's new clothes?
Mullane, K., & Williams, M. J. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.01.004 · Cited by 30
McGivern, J. V., & Ebert, A. D. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.012 · Cited by 30
GuiltyTargets: Prioritization of Novel Therapeutic Targets With Network Representation Learning
Muslu, Ö., Hoyt, C. T., Lacerda, M., Hofmann‐Apitius, M., & Frohlich, H. (2020) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2020.3003830 · Cited by 32
Reproducibility Problems of Amyloid-β Self-Assembly and How to Deal With Them
Faller, P., & Hureau, C. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2020.611227 · Cited by 36
Inhibition of a lower potency target drives the anticancer activity of a clinical p38 inhibitor
Bhattacharjee, D., Bakar, J., Chitnis, S. P., Sausville, E. L., Ashtekar, K. D., Mendelson, B. E., Long, K., Smith, J. C., Heppner, D. E., & Sheltzer, J. M. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.09.013 · Cited by 30
Elucidating Substrate Promiscuity in the Human Cytochrome 3A4
Hayes, C., Ansbro, D., & Kontoyianni, M. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci4006782 · Cited by 28
Drug candidates derailed in case of mistaken identity
Ledford, H. K. (2012) · Nature · doi:10.1038/483519a · Cited by 29
Wong, H., Bohnert, T., Damian-Iordache, V., Gibson, C., Hsu, C.-P., Krishnatry, A. S., Liederer, B. M., Lin, J., Lu, Q., Mettetal, J. T., et al. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.04.015 · Cited by 27
Alzheimer's Disease and the “Valley of Death”: Not Enough Guidance from Human Brain Tissue?
Beach, T. G. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-129020 · Cited by 28
Estrogen receptor alpha gene amplification in breast cancer: 25 years of debate
Holst, F. (2016) · World Journal of Clinical Oncology · doi:10.5306/wjco.v7.i2.160 · Cited by 27
Emerging technologies for prediction of drug candidate efficacy in the preclinical pipeline
Menshykau, D. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.04.019 · Cited by 27
Jaki, T., & Wason, J. M. S. (2018) · BMC Cardiovascular Disorders · doi:10.1186/s12872-018-0956-4 · Cited by 27
Development of cell metabolite analysis on microfluidic platform
Lin, L., & Lin, J. (2015) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2015.09.003 · Cited by 27
Addressing potential prior‐data conflict when using informative priors in proof‐of‐concept studies
Mutsvari, T., Tytgat, D., & Walley, R. J. (2015) · Pharmaceutical Statistics · doi:10.1002/pst.1722 · Cited by 29
Heroux, M. A. (2015) · ACM Transactions on Mathematical Software · doi:10.1145/2743015 · Cited by 27
The Search for Efficacious New Therapies in Sepsis Needs to Embrace Heterogeneity
Scicluna, B. P., & Baillie, J. K. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201811-2148ed · Cited by 28
AI-Driven Decision-Making Applications in Pharmaceutical Sciences
Yingngam, B., Navabhatra, A., & Sillapapibool, P. (2024) · Advances in media, entertainment and the arts (AMEA) book series · doi:10.4018/979-8-3693-0639-0.ch001 · Cited by 39
Grossi, F., Genova, C., Gaitan, N. S. D., Bello, M. G. D., Rijavec, E., Barletta, G., Sini, C., Donato, C., Beltramini, S., Pronzato, P., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.03.021 · Cited by 26
Replication in Imaging Genetics: The Case of Threat-Related Amygdala Reactivity
Avinun, R., Nevo, A., Knodt, A. R., Elliott, M. L., & Hariri, A. R. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.11.010 · Cited by 26
Lohani, S., Cooper, H., Jin, X., Nissley, B. P., Manser, K., Rakes, L. H., Cummings, J. J., Fauty, S. E., & Bak, A. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24088 · Cited by 25
Kjellsson, M. C., Cosson, V. F., Mazer, N. A., Frey, N., & Karlsson, M. O. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.86 · Cited by 25
Guetterman, T. C., Fetters, M. D., Legocki, L. J., Mawocha, S., Barsan, W. G., Lewis, R. J., Berry, D. A., & Meurer, W. J. (2015) · Clinical Research and Regulatory Affairs · doi:10.3109/10601333.2015.1079217 · Cited by 25
Marshall, L. J., Triunfol, M., & Seidle, T. (2020) · Animals · doi:10.3390/ani10101923 · Cited by 29
Academic Discovery of Anticancer Drugs: Historic and Future Perspectives
Carugo, A., & Draetta, G. F. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055645 · Cited by 30
Pistollato, F., Bernasconi, C., McCarthy, J., Campia, I., Desaintes, C., Wittwehr, C., Deceuninck, P., & Whelan, M. (2020) · Animals · doi:10.3390/ani10071194 · Cited by 27
A Quantitative Process for Enhancing End of Phase 2 Decisions
Sabin, T., Matcham, J., Bray, S. L., Copas, A. J., & Parmar, M. (2013) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2013.852617 · Cited by 26
Lim, H., Chong, Y. P., Noh, Y.-H., Jung, J. A., & Kim, Y. S. (2014) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12123 · Cited by 24
Genetic Interactions of STAT3 and Anticancer Drug Development
Fang, B. (2014) · Cancers · doi:10.3390/cancers6010494 · Cited by 27
Detection of Statin Cytotoxicity Is Increased in Cells Expressing the OATP1B1 Transporter
Zhang, X., Scialis, R. J., Feng, B., & Leach, K. L. (2013) · Toxicological Sciences · doi:10.1093/toxsci/kft085 · Cited by 26
ERCC1 as Predictor of Platinum Benefit in Non–Small-Cell Lung Cancer
Postel-Vinay, S. C., & Soria, J. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.5053 · Cited by 25
Wilson, F. J., Leiser, S. C., Ivarsson, M., Christensen, S. R., & Bastlund, J. F. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.08.001 · Cited by 27
Systems biology‐embedded target validation: improving efficacy in drug discovery
Vandamme, D., Minke, B., Fitzmaurice, W., Kholodenko, B. Ν., & Kölch, W. (2013) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1253 · Cited by 25
Targeting Peroxisome Proliferator-Activated Receptor-β/δ (PPARβ/δ) for Cancer Chemoprevention
Peters, J. M., Yao, P., & Gonzalez, F. J. (2015) · Current Pharmacology Reports · doi:10.1007/s40495-015-0026-x · Cited by 24
Transporter-mediated tissue targeting of therapeutic molecules in drug discovery
Zhou, J., Xu, J., Huang, Z., & Wang, M. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.01.016 · Cited by 22
Paul, S. M., & Lewis-Hall, F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004452 · Cited by 22
Hey, S. P., Heilig, C. M., & Weijer, C. (2013) · Trials · doi:10.1186/1745-6215-14-159 · Cited by 26
Swaroop, M., Thorne, N., Rao, M. S., Austin, C. P., McKew, J. C., & Zheng, W. (2012) · SLAS Discovery · doi:10.1177/1087057112456877 · Cited by 22
Pharmacology in Drug Discovery
Kenakin, T. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803752-2.00011-9 · Cited by 22
Cancer in the news: Bias and quality in media reporting of cancer research
Amberg, A., & Saunders, D. N. (2020) · PLoS ONE · doi:10.1371/journal.pone.0242133 · Cited by 23
Silverstein, P., Pennington, C. R., Branney, P., O'Connor, D. B., Lawlor, E., O'Brien, E., & Lynott, D. (2024) · British Journal of Psychology · doi:10.1111/bjop.12700 · Cited by 27
McEntire, R., Szalkowski, D., Butler, J., Kuo, M. S., Chang, M., Chang, M., Freeman, D., McQuay, S., Patel, J. H., McGlashen, M. L., et al. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.03.006 · Cited by 23
Volz, P., Schilrreff, P., Brodwolf, R., Wolff, C., Stellmacher, J., Balke, J., Morilla, M. J., Zoschke, C., Schäfer‐Korting, M., & Alexiev, U. (2017) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13473 · Cited by 21
Renal Safety Pharmacology in Drug Discovery and Development
Benjamin, A., da Costa, A. N., Delaunois, A. G., Rosseels, M.-L. A., & Valentin, J. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-662-46943-9_13 · Cited by 20
Has the Time Come for Predictive Computer Modeling in CNS Drug Discovery and Development?
Geerts, H., Spiros, Ä., Roberts, P., & Carr, R. A. (2012) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2012.17 · Cited by 20
Substituted tetrazoles as multipurpose screening compounds
Rüger, N., Fassauer, G. M., Bock, C., Emmrich, T., Bodtke, A., & Link, A. (2016) · Molecular Diversity · doi:10.1007/s11030-016-9711-x · Cited by 20
Srikumar, B. N., Paschapur, M. S., Kalidindi, N., Adepu, B., Das, M. L., Sreedhara, M. V., Kuchibhotla, V. K., Pieschl, R. L., Li, Y.-W., Ega, D. S. P., et al. (2017) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2017.09.003 · Cited by 21
Shift in the paradigm towards next-generation microbiology
Stres, B., & Kronegger, L. (2019) · FEMS Microbiology Letters · doi:10.1093/femsle/fnz159 · Cited by 20
Gendered Innovation in Health and Medicine
Schiebinger, L. L., & Klinge, I. I. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-77932-4_39 · Cited by 25
Why is publication of negative clinical trial data important?
Hayes, A. G., & Hunter, J. A. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02215.x · Cited by 20
Challenges and Opportunities Toward Enabling Phenotypic Screening of Complex and 3D Cell Models
Horman, S. R., Hogan, C. J., Reyes, K. D., Lo, F., & Antczak, C. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.14.163 · Cited by 24
Tagne, A. M., Cassina, N., Furgiuele, A., Storelli, E., Cosentino, M., & Marino, F. (2020) · Journal of Academic Ethics · doi:10.1007/s10805-020-09359-0 · Cited by 20
Bias translation: The final frontier?
Kenakin, T. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16335 · Cited by 26
Multiplicity and replicability: two sides of the same coin
Bretz, F., & Westfall, P. H. (2014) · Pharmaceutical Statistics · doi:10.1002/pst.1648 · Cited by 19
Predicting the Efficacy of an Oral Paclitaxel Formulation (DHP107) Through Modeling and Simulation
Lim, H., Bae, K., Jung, J., Noh, Y.-H., Hwang, A.-K., Jo, Y.-W., Hong, Y. S., Kim, K., Lee, J., Park, S., et al. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.12.009 · Cited by 20
The implications of model-informed drug discovery and development for tuberculosis
Muliaditan, M., Davies, G., Simonsson, U. S. H., Gillespie, S. H., & Pasqua, O. E. D. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.09.004 · Cited by 18
Identification of Ligands and Translation to Clinical Applications
Haberkorn, U., Mier, W., Kopka, K., Herold‐Mende, C. C., Altmann, A., & Babich, J. W. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.186791 · Cited by 19
Muliaditan, M., & Pasqua, O. E. D. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14371 · Cited by 22
Addressing the Right Targets in Oncology: Challenges and Alternative Approaches
Stock, J. K., Jones, N. P., Hammonds, T. R., Roffey, J., & Dillon, C. (2015) · SLAS DISCOVERY · doi:10.1177/1087057114564349 · Cited by 21
Translation Strategy for the Qualification of Drug-induced Vascular Injury Biomarkers
Bendjama, K., Guionaud, S., Aras, G., Arber, N., Badimón, L., Bamberger, U., Bratfalean, D., Brott, D., David, M., Doessegger, L., et al. (2014) · Toxicologic Pathology · doi:10.1177/0192623314527644 · Cited by 20
Comparison of Kinetic Models for Dual-Tracer Receptor Concentration Imaging in Tumors.
Hamzei, N., Samkoe, K. S., Elliott, J. T., Holt, R. W., Gunn, J. R., Hasan, T. G., Pogue, B. W., & Tichauer, K. M. (2014) · PubMed · Cited by 19
Personalized Medicine: A Review with Regard to Biomarkers
Foroutan, B. (2015) · Journal of Bioequivalence & Bioavailability · doi:10.4172/jbb.1000248 · Cited by 22
Atia, G. A. N., Shalaby, H. K., Zehravi, M., Ghobashy, M. M., Ahmad, Z., Khan, F. S., Dey, A., Rahman, M. H., Joo, S. W., Barai, H. R., et al. (2022) · Polymers · doi:10.3390/polym14142964 · Cited by 18
Williams, R. J., Walker, I., & Takle, A. K. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.01.020 · Cited by 18
Karthivashan, G., Park, S., Kim, J.-S., Cho, D.-Y., Ganesan, P., & Choi, D. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081735 · Cited by 20
Evolutionary and genetic features of drug targets
Quan, Y., Wang, Z., Chu, X., & Zhang, H. (2018) · Medicinal Research Reviews · doi:10.1002/med.21487 · Cited by 19
You-on-a-chip’ for precision medicine
Low, L. A., & Tagle, D. A. (2018) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2018.1456333 · Cited by 18
Parkinson’s disease research: adopting a more human perspective to accelerate advances
Marshall, L. J., & Willett, C. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.09.010 · Cited by 19
Contreras‐Baeza, Y., Ceballo, S., Arce‐Molina, R., Sandoval, P. Y., Alegría, K., Barros, L. F., & Martín, A. S. (2019) · PLoS ONE · doi:10.1371/journal.pone.0224527 · Cited by 19
Multiparametric Assays for Accelerating Early Drug Discovery
Herholt, A., Galinski, S., Geyer, P. E., Rossner, M. J., & Wehr, M. C. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.02.005 · Cited by 21
Measurement and models accounting for cell death capture hidden variation in compound response
Bae, S. Y., Guan, N., Yan, R., Warner, K., Taylor, S. D., & Meyer, A. S. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2462-8 · Cited by 19
Takahashi, N., Higa, A., Hiyama, G., Tamura, H., Hoshi, H., Dobashi, Y., Katahira, K., Ishihara, H., Takagi, K., Goda, K., et al. (2021) · Oncology Letters · doi:10.3892/ol.2021.12667 · Cited by 19
Evolving role of modeling and simulation in drug development
Lim, H. (2019) · Translational and Clinical Pharmacology · doi:10.12793/tcp.2019.27.1.19 · Cited by 21
Is There a Space-Based Technology Solution to Problems with Preclinical Drug Toxicity Testing?
Hammond, T. G., Allen, P., & Birdsall, H. H. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1942-0 · Cited by 17
Altunel, E., Roghani, R. S., Chen, K., Kim, S. Y., McCall, S. J., Ware, K. E., Shen, X., Somarelli, J. A., & Hsu, D. S. (2020) · BMC Cancer · doi:10.1186/s12885-020-07090-y · Cited by 18
Naveed, H., Hameed, U. F. S., Harrus, D., Bourguet, W., Arold, S. T., & Gao, X. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv477 · Cited by 16
Translating pharmacology models effectively to predict therapeutic benefit
Dudal, S., Bissantz, C., Caruso, A., David‐Pierson, P., Driessen, W. H. P., Koller, E., Krippendorff, B., Lechmann, M., Olivares‐Morales, A., Paehler, A., et al. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.03.009 · Cited by 22
Liggi, S., Drakakis, G., Hendry, A. E., Hanson, K., Brewerton, S. C., Wheeler, G. N., Bodkin, M. J., Evans, D. A. P., & Bender, A. (2013) · Molecular Informatics · doi:10.1002/minf.201300102 · Cited by 20
Dambach, D. M., & Uppal, H. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003497 · Cited by 17
Ashton, R. (2014) · ALTEX · doi:10.14573/altex.1403122 · Cited by 19
New Lives for Seven Transmembrane Receptors as Drug Targets
Kenakin, T. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.09.004 · Cited by 16
Clinical Trials in the Genomic Era
Joffe, E., Iasonos, A. E., & Younes, A. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.8891 · Cited by 18
Metadata
- Authors
- Arrowsmith, J.
- Affiliations
- Thomson Reuters (United Kingdom) (GB)
- Corresponding author
- Arrowsmith, John
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-04-29
- Volume
- 10
- Issue
- 5
- Pages
- 328-329
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2065540447
- Cited by
- 622
- References
- 0
- Citations by year
- 2026: 12 · 2025: 18 · 2024: 22 · 2023: 14 · 2022: 21 · 2021: 25 · 2020: 36 · 2019: 44 · 2018: 37 · 2017: 54 · 2016: 64 · 2015: 66 · 2014: 66 · 2013: 88 · 2012: 41
- Type
- other
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Science, Research, and Medicine
- Keywords
- drug development failure, clinical trial attrition, drug repurposing, translational research
- MeSH terms
- Drug Industry, Pharmaceutical Preparations, Humans, Drug Design, Treatment Failure, Clinical Trials, Phase II as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.